HK Stock MarketDetailed Quotes
02096 SIMCERE PHARMA
- 6.860
- +0.180+2.69%
Trading Nov 27 15:32 CST
17.33BMarket Cap-14351P/E (TTM)
6.880High6.650Low2.12MVolume6.680Open6.680Pre Close14.34MTurnover0.08%Turnover Ratio21.99P/E (Static)2.53BShares7.63052wk High2.29P/B17.33BFloat Cap4.76452wk Low0.18Dividend TTM2.53BShs Float14.453Historical High0.182Dividend LFY3.44%Amplitude4.764Historical Low6.755Avg Price1000Lot Size2.65%Div YieldTTM2.65%Div Yield LFY
SIMCERE PHARMA Key Stats
All
YOY
| (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -7.93%3.11B | 4.49%6.61B | 25.26%3.38B | 26.49%6.32B | 27.34%2.7B | 10.89%5B | 10.11%2.12B | -10.48%4.51B | -20.24%1.93B | 11.57%5.04B |
| Operating income | -7.93%3.11B | 4.49%6.61B | 25.26%3.38B | 26.49%6.32B | 27.34%2.7B | 10.89%5B | 10.11%2.12B | -10.48%4.51B | -20.24%1.93B | 11.57%5.04B |
| Cost of sales | 20.57%-651.59M | -22.32%-1.62B | -47.18%-820.36M | -22.91%-1.33B | -21.97%-557.37M | -20.01%-1.08B | -17.74%-456.98M | -1.29%-899.93M | 9.41%-388.13M | -15.21%-888.49M |
| Operating expenses | 20.57%-651.59M | -22.32%-1.62B | -47.18%-820.36M | -22.91%-1.33B | -21.97%-557.37M | -20.01%-1.08B | -17.74%-456.98M | -1.29%-899.93M | 9.41%-388.13M | -15.21%-888.49M |
| Gross profit | -3.88%2.46B | -0.25%4.98B | 19.56%2.56B | 27.47%5B | 28.82%2.14B | 8.62%3.92B | 8.18%1.66B | -13.00%3.61B | -22.58%1.54B | 10.82%4.15B |
| Selling expenses | 7.36%-1.16B | 1.93%-2.36B | -21.19%-1.25B | -17.97%-2.4B | -23.99%-1.03B | -29.70%-2.04B | -32.09%-830.18M | 22.11%-1.57B | 39.38%-628.5M | 9.25%-2.02B |
| Administrative expenses | 10.36%-230.81M | -11.93%-499.28M | -36.60%-257.47M | -21.66%-446.08M | -15.29%-188.48M | 10.89%-366.66M | 15.50%-163.48M | -17.00%-411.48M | -24.33%-193.46M | -21.18%-351.68M |
| Research and development expenses | 27.04%-566.13M | 9.56%-1.56B | -19.09%-775.89M | -21.99%-1.73B | -3.95%-651.54M | -24.06%-1.42B | -38.03%-626.8M | -59.40%-1.14B | -79.82%-454.09M | -60.22%-716.41M |
| Impairment and provision | 94.36%1.83M | -93.79%867K | -95.31%939K | 188.27%13.97M | 150.54%20.03M | ---15.83M | ---39.63M | ---- | ---- | ---- |
| -Other impairment is provision | 94.36%1.83M | -93.79%867K | -95.31%939K | 188.27%13.97M | 150.54%20.03M | ---15.83M | ---39.63M | ---- | ---- | ---- |
| Special items of operating profit | -100.94%-19.04M | -65.91%145.59M | 905.89%2.03B | -68.71%427.08M | -145.53%-251.85M | 208.84%1.36B | 1,410.37%553.17M | 311.26%441.89M | -28.17%36.63M | -32.01%107.45M |
| Operating profit | -78.70%492.16M | -17.29%711.8M | 5,521.48%2.31B | -40.59%860.61M | -92.61%41.11M | 56.29%1.45B | 86.71%556.11M | -20.87%926.84M | -49.65%297.85M | 24.35%1.17B |
| Financing income | -17.86%25.41M | -8.20%54.96M | 2.23%30.94M | -12.33%59.87M | 8.02%30.26M | 160.16%68.29M | 158.17%28.01M | -24.41%26.25M | -56.40%10.85M | -4.22%34.72M |
| Financing cost | -29.26%-23.47M | -0.47%-34.57M | 1.93%-18.16M | 51.43%-34.41M | 60.94%-18.51M | 47.02%-70.85M | 40.44%-47.4M | -15.33%-133.73M | -22.78%-79.58M | -143.94%-115.96M |
| Share of profits of associates | 102.27%18K | 4,963.48%5.82M | -104.91%-793K | 100.26%115K | 97.38%-387K | -216.53%-43.92M | -238.85%-14.75M | -70.67%-13.87M | -186.76%-4.35M | -403.03%-8.13M |
| Share of profit from joint venture company | -51.69%573K | 2,594.67%2.02M | 2,137.74%1.19M | 127.78%75K | 139.55%53K | 31.30%-270K | -235.00%-134K | -191.11%-393K | ---40K | ---135K |
| Earning before tax | -78.72%494.69M | -16.50%740.04M | 4,325.15%2.32B | -36.78%886.25M | -89.94%52.52M | 74.12%1.4B | 132.20%521.84M | -25.58%805.09M | -59.15%224.73M | 16.44%1.08B |
| Tax | 25.81%-38.09M | -164.45%-26.09M | -646.35%-51.35M | -58.32%40.48M | -71.57%9.4M | 168.98%97.12M | 182.85%33.06M | -80.07%-140.8M | 55.24%-39.9M | 59.98%-78.19M |
| After-tax profit from continuing operations | -79.91%456.6M | -22.96%713.95M | 3,570.60%2.27B | -38.17%926.73M | -88.84%61.92M | 125.64%1.5B | 200.21%554.9M | -33.81%664.29M | -59.91%184.84M | 36.79%1B |
| Earning after tax | -79.91%456.6M | -22.96%713.95M | 3,570.60%2.27B | -38.17%926.73M | -88.84%61.92M | 125.64%1.5B | 200.21%554.9M | -33.81%664.29M | -59.91%184.84M | 36.79%1B |
| Minority profit | ---- | 80.39%-811K | 56.47%-811K | 49.41%-4.14M | 36.18%-1.86M | -55.80%-8.18M | -327.38%-2.92M | ---5.25M | ---683K | ---- |
| Profit attributable to shareholders | -79.92%456.6M | -23.22%714.76M | 3,464.66%2.27B | -38.23%930.87M | -88.57%63.78M | 125.10%1.51B | 200.68%557.81M | -33.29%669.53M | -59.76%185.52M | 36.79%1B |
| Basic earnings per share | -79.31%0.18 | -25.00%0.27 | 4,250.00%0.87 | -37.93%0.36 | -90.48%0.02 | 107.14%0.58 | 162.50%0.21 | -34.88%0.28 | -60.00%0.08 | 38.71%0.43 |
| Diluted earnings per share | -79.07%0.18 | -25.00%0.27 | 4,200.00%0.86 | -37.93%0.36 | -90.48%0.02 | 107.14%0.58 | 162.50%0.21 | -34.88%0.28 | -60.00%0.08 | 38.71%0.43 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | KPMG | -- | KPMG | -- | KPMG | -- | KPMG | -- | KPMG |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
% Chg
No Data